The Association of British Clinical Diabetologists (ABCD) has updated its position statement on the use of SGLT-2 inhibitors in type 1 diabetes. The update aims to mitigate a risk of higher incidence of diabetic ketoacidosis without significant hyperglycaemiaand other potential complications in people taking the class of drug. The abstract reads: “Particular caution needs to be exercised … Continue reading SGLT-2 inhibitors in type 1 diabetes position statement updated